166 related articles for article (PubMed ID: 38196545)
21. Utilization of Immunotherapy for the Treatment of Hepatocellular Carcinoma in the Peri-Transplant Setting: Transplant Oncology View.
Abdelrahim M; Esmail A; Saharia A; Abudayyeh A; Abdel-Wahab N; Diab A; Murakami N; Kaseb AO; Chang JC; Gaber AO; Ghobrial RM
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406533
[TBL] [Abstract][Full Text] [Related]
22. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Abdel-Rahman O; Elsayed Z
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011313. PubMed ID: 31978267
[TBL] [Abstract][Full Text] [Related]
23. When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.
Gu Y; Xu S; Wang Z; Yang J; Zheng S; Wei Q; Liu Z; Xu X
Chin J Cancer Res; 2023 Apr; 35(2):92-107. PubMed ID: 37180832
[TBL] [Abstract][Full Text] [Related]
24. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors.
Gao Q; Anwar IJ; Abraham N; Barbas AS
Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944927
[TBL] [Abstract][Full Text] [Related]
25. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant.
Anugwom CM; Leventhal TM; Debes JD
Hepatoma Res; 2022; 8():. PubMed ID: 35693455
[TBL] [Abstract][Full Text] [Related]
26. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
[TBL] [Abstract][Full Text] [Related]
27. Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
Roessler D; Öcal O; Philipp AB; Markwardt D; Munker S; Mayerle J; Jochheim LS; Hammer K; Lange CM; Geier A; Seidensticker M; Reiter FP; De Toni EN; Ben Khaled N
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3065-3073. PubMed ID: 35864269
[TBL] [Abstract][Full Text] [Related]
28. Stable liver graft post anti-PD1 therapy as a bridge to transplantation in an adolescent with hepatocellular carcinoma.
Kang E; Martinez M; Moisander-Joyce H; Saenger YM; Griesemer AD; Kato T; Yamashiro DJ; Remotti H; Gartrell RD
Pediatr Transplant; 2022 May; 26(3):e14209. PubMed ID: 34907641
[TBL] [Abstract][Full Text] [Related]
29. Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
Jiang J; Huang H; Chen R; Lin Y; Ling Q
Front Immunol; 2023; 14():1092401. PubMed ID: 36875077
[TBL] [Abstract][Full Text] [Related]
30. High serum IL-6 correlates with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma.
Yang H; Kang B; Ha Y; Lee SH; Kim I; Kim H; Lee WS; Kim G; Jung S; Rha SY; Gaillard VE; Cheon J; Kim C; Chon HJ
JHEP Rep; 2023 Apr; 5(4):100672. PubMed ID: 36866388
[TBL] [Abstract][Full Text] [Related]
31. Emerging drugs for the treatment of hepatocellular carcinoma.
Ayoub WS; Jones PD; Yang JD; Martin P
Expert Opin Emerg Drugs; 2022 Jun; 27(2):141-149. PubMed ID: 35642526
[TBL] [Abstract][Full Text] [Related]
32. Current Landscape of Immune Checkpoint Inhibitor Therapy for Hepatocellular Carcinoma.
Ruff SM; Manne A; Cloyd JM; Dillhoff M; Ejaz A; Pawlik TM
Curr Oncol; 2023 Jun; 30(6):5863-5875. PubMed ID: 37366922
[TBL] [Abstract][Full Text] [Related]
33. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.
de Castria TB; Khalil DN; Harding JJ; O'Reilly EM; Abou-Alfa GK
Future Oncol; 2022 Oct; 18(33):3769-3782. PubMed ID: 36399155
[TBL] [Abstract][Full Text] [Related]
34. Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: Monotherapies and Combined Therapies.
Ouyang T; Kan X; Zheng C
Front Oncol; 2022; 12():898964. PubMed ID: 35785169
[TBL] [Abstract][Full Text] [Related]
35. Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma.
Alden SL; Lim M; Kao C; Shu D; Singal AG; Noonan A; Griffith P; Baretti M; Ho WJ; Kamel I; Yarchoan M; Hsiehchen D
Cancer Res Commun; 2023 Jul; 3(7):1312-1317. PubMed ID: 37484200
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A; Jacquin M; Rebucci-Peixoto M; Pureur D; Ghiringhelli F; Assenat E; Hammel P; Rosmorduc O; Stouvenot M; Allaire M; Bouattour M; Regnault H; Fratte S; Raymond E; Soularue E; Husson-Wetzel S; Di Martino V; Muller A; Clairet AL; Fagnoni-Legat C; Adotevi O; Meurisse A; Vernerey D; Borg C
BMC Cancer; 2023 Jul; 23(1):710. PubMed ID: 37516867
[TBL] [Abstract][Full Text] [Related]
37. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
Chen Y; Hu H; Yuan X; Fan X; Zhang C
Front Immunol; 2022; 13():896752. PubMed ID: 35757756
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapies for advanced hepatocellular carcinoma.
Sun LY; Zhang KJ; Xie YM; Liu JW; Xiao ZQ
Front Pharmacol; 2023; 14():1138493. PubMed ID: 37025485
[TBL] [Abstract][Full Text] [Related]
39. Liver Allograft Failure After Nivolumab Treatment-A Case Report With Systematic Literature Research.
Gassmann D; Weiler S; Mertens JC; Reiner CS; Vrugt B; Nägeli M; Mangana J; Müllhaupt B; Jenni F; Misselwitz B
Transplant Direct; 2018 Aug; 4(8):e376. PubMed ID: 30255136
[TBL] [Abstract][Full Text] [Related]
40. Impact and Novel Perspective of Immune Checkpoint Inhibitors in Patients with Early and Intermediate Stage HCC.
Marzi L; Mega A; Gitto S; Pelizzaro F; Seeber A; Spizzo G
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]